Intravaginal Colposeptine Therapy For Bacterial Vaginosis-a Randomized Controlled Trial

Background and ObjectiveColposeptine (Chlorquinaldol/Promestriene) can kill the pathogenic bacteria andincrease the number of lactobacillus and reconstruct the vaginal microecosystem. Inthis study, we compared the clinical efficacy and the impact on vaginalmicroecosystem of Colposeptine with oral metronidazole.Materials and MethodsPatients with BV were divided into three groups: oral metronidazole for 7 days,intrvaginal Colposeptine for 12 days and intrvaginal Colposeptine for 18 days,respectively. Curative effect was evaluated 1 month after treatment. Vaginalmicroecology was studied.ResultsOne hundred and sixteen cases of patients with BV finished the follow up. Theeffective rates of oral metronidazole, intrvaginal Colposeptine for 12 days andintrvaginal Colposeptine for 18 days were 83.64%, 53.33% and 87.10% respectively.There were no significant difference between oral metronidazole and intrvaginalColposeptine for 18 days ( Pï¹¥0.05), and significant difference between intrvaginalColposeptine for 12 days and oral metronidazole, intrvaginal Colposeptine for 12 daysand intrvaginal Colposeptine for 18 days (P<0.05). The cure rates according to theNugent standard were 81.82%, 60.00% and 74.19% respectively in the three groups.There were no significantly differences between all of the groups ( Pï¹¥0.05). Thenumber of lactobacillus was increased and the number of gardnerella vaginalis wasreduced in vagina of the patients in all three groups (P<0.05).ConclusionEeffective rates of intrvaginal Colposeptine for 18 days is equal to that of oralmetronidazole for 7 days. All of the three groups can increase the number oflactobacillus and reduce the number of gardnerella vaginalis in vagina of the patients.